Integra Lifesciences Holdings (IART) Cash from Investing Activities (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Cash from Investing Activities data on file, last reported at -$14.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 58.66% year-over-year to -$14.8 million; the trailing twelve-month figure through Mar 2026 stood at -$87.0 million (up 76.66% YoY), and the FY2025 full-year result was -$108.1 million, up 72.35% from the prior year.
• Cash from Investing Activities improved to -$14.8 million in Q1 2026, from -$34.9 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $14.8 million in Q3 2022 to a low of -$322.2 million in Q2 2024.
• A 5-year average of -$39.2 million and a median of -$15.5 million in 2023 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities surged 274.69% in 2022 and plunged 1972.28% in 2024, its largest moves.
• Tracing IART's Cash from Investing Activities over 5 years: stood at -$54.8 million in 2022, then declined by 4.39% to -$57.2 million in 2023, then jumped by 92.58% to -$4.2 million in 2024, then tumbled by 721.53% to -$34.9 million in 2025, then soared by 57.46% to -$14.8 million in 2026.
• Business Quant data shows IART's Cash from Investing Activities at -$14.8 million in Q1 2026, -$34.9 million in Q4 2025, and -$15.6 million in Q3 2025.